Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: infliximab

ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines

Thomas R. Collins  |  February 1, 2013

People with rheumatic diseases can be considered to receive flu and pneumococcal vaccines even if they’re on immunosuppressive drugs

Filed under:ConditionsMeeting Reports Tagged with:DrugsImmune Systempatient carevaccine

ACR/ARHP Annual Meeting 2012: Global Perspectives Make Rheumatology Meeting an International Affair

Susan Bernstein  |  January 1, 2013

Attendees from every corner of the world came to the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting with different educational and professional goals

Filed under:Education & TrainingMeeting Reports Tagged with:ACR/ARHP Annual MeetingEducation

Coding Corner Question: December

Staff  |  December 1, 2012

Test your coding knowledge for an office visit by a 60-year-old patient with severe rheumatoid arthritis who has an adverse reaction to an infliximab infusion, requiring her IV to be flushed with saline and pushed with diphenhydramine.

Filed under:Billing/CodingPractice Support Tagged with:BillingCodingdruginfliximabMethotrexatePractice Managementprednisonerheumatologist

Coding Corner Answer: December Coding Challenge

Staff  |  December 1, 2012

Coding for an office visit by a patient with severe rheumatoid arthritis who experiences an adverse reaction to an infliximab infusion and has her IV flushed with saline and pushed with diphenhydramine.

Filed under:Billing/CodingConditionsPractice SupportRheumatoid Arthritis Tagged with:BillingCodingdruginfliximabPractice ManagementRheumatoid arthritisrheumatologist

What Rheumatologists Should Look for in Diagnosing SAPHO Syndrome

Richard Brasington, MD  |  November 1, 2012

SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis) is an obscure condition that can vex patients and clinicians

Filed under:Clinical Criteria/GuidelinesConditionsOsteoarthritis and Bone Disorders Tagged with:anti-inflammatorybonecase reportimaginginfliximabPainpatient careradiographrheumatologistSAPHOsynovitisTreatment

Rheumatology Drug Updates: Apremilast, Golimumab, and More

Michele B. Kaufman, PharmD, BCGP  |  November 1, 2012

Information on new approvals and medication safety rheumatologists need to know

Filed under:AnalgesicsAxial SpondyloarthritisBiologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:Ankylosing SpondylitisBiologicsBiosimilarsdrugFDAinfliximabJAK inhibitorsjanus kinaseMethotrexatePipelinePolymyalgia RheumaticaprednisonePsoriatic ArthritisRheumatoid arthritisSafetyTofacitinib

South Korea Okays First Officially Approved Monoclonal Antibody for RA

Kurt Ullman  |  October 17, 2012

11 Products Looking for U.S. Marketing Nod

Filed under:Uncategorized Tagged with:Biosimilarsgeneric drugs

EULAR 2012: Rewards in Risk Factor Research

Thomas R. Collins  |  September 5, 2012

Investigations of infection and comorbidities offers hints to better understanding of rheumatoid arthritis.

Filed under:ConditionsEULAR/OtherMeeting ReportsResearch RheumRheumatoid Arthritis Tagged with:EULARInfectionInternationalPainpatient careResearchRheumatoid arthritisrheumatologist

EULAR 2012: Remission the New Normal for Rheumatoid Arthritis

Thomas R. Collins  |  August 8, 2012

Advances in the rheumatology clinic are promising, two experts say.

Filed under:Biologics/DMARDsClinical Criteria/GuidelinesConditionsDrug UpdatesEULAR/OtherMeeting ReportsRheumatoid Arthritis Tagged with:BiologicsEULARHYDROXYCHLOROQUINEinfliximabInternationalMethotrexatepatient careRheumatoid arthritisrheumatologisttocilizumab

Coding Corner Question: August Coding Challenge

Staff  |  August 8, 2012

A 43-year-old female established patient diagnosed with rheumatoid arthritis comes to the office for her first infliximab infusion.

Filed under:Billing/CodingConditionsPractice SupportRheumatoid Arthritis Tagged with:anti-inflammatoryBillingCodingdrugimaginginfliximabPractice ManagementRheumatoid arthritisrheumatologist

  • « Previous Page
  • 1
  • …
  • 32
  • 33
  • 34
  • 35
  • 36
  • …
  • 41
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences